These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 38735710)

  • 1. Study on prediction of early adverse events by CapeOX therapy in patients with colorectal cancer.
    Kumihashi Y; Kasai Y; Akagawa T; Yuasa Y; Ishikura H; Sato Y
    J Med Invest; 2024; 71(1.2):141-147. PubMed ID: 38735710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk Factors for Thrombocytopenia Induced by Capecitabine Plus Oxaliplatin Therapy in Patients With Colorectal Cancer.
    Kato N; Nakai T; Kodama S; Koyama S; Nakane S; Wada Y; Oda H; Katayama H; Mase H; Miyagawa Y; Miyazaki M; Yamada S; Yamada K
    In Vivo; 2024; 38(3):1243-1252. PubMed ID: 38688620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An open-label study of the safety and tolerability of pazopanib in combination with FOLFOX6 or CapeOx in patients with colorectal cancer.
    Brady J; Corrie P; Chau I; Digumarti R; Adams LM; Botbyl J; Laubscher KH; Midgley RS; Mallath M
    Invest New Drugs; 2013 Oct; 31(5):1228-35. PubMed ID: 23456563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Proton Pump Inhibitors on FOLFOX and CapeOx Regimens in Colorectal Cancer.
    Wong GG; Ha V; Chu MP; Dersch-Mills D; Ghosh S; Chambers CR; Sawyer MB
    Clin Colorectal Cancer; 2019 Mar; 18(1):72-79. PubMed ID: 30551953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Retrospective analysis of the bevacizumab and CapeOX combination in untreated metastatic/recurrent colorectal cancer].
    Miyamae Y; Takahashi K; Igarashi T; Tanaka K; Takahashi N; Hirai K; Tsukagoshi H; Ogawa H; Yoshinari D; Sunose Y; Takeyoshi I
    Gan To Kagaku Ryoho; 2014 Jun; 41(6):737-41. PubMed ID: 25129085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial.
    Hong YS; Park YS; Lim HY; Lee J; Kim TW; Kim KP; Kim SY; Baek JY; Kim JH; Lee KW; Chung IJ; Cho SH; Lee KH; Shin SJ; Kang HJ; Shin DB; Jo SJ; Lee JW
    Lancet Oncol; 2012 Nov; 13(11):1125-32. PubMed ID: 23062232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protocol of a randomised phase III clinical trial of sequential capecitabine or 5-fluorouracil plus bevacizumab (Cape/5-FU-Bmab) to capecitabine or 5-fluorouracil plus oxaliplatin plus bevacizumab (CapeOX/mFOLFOX6-Bmab) versus combination CapeOX/mFOLFOX6-Bmab in advanced colorectal cancer: the C-cubed (C3) study.
    Nagasaka T; Mishima H; Sawaki A; Shimokawa M; Inukai M; Shinozaki K; Tanioka H; Nasu J; Nishina T; Hazama S; Okajima M; Yamaguchi Y
    BMJ Open; 2016 Jun; 6(6):e011454. PubMed ID: 27256093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer].
    Xie BW; Zang L; Ma JJ; Sun J; Yang X; Wang ML; Lu AG; Hu WG; Zheng MH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):138-144. PubMed ID: 33508919
    [No Abstract]   [Full Text] [Related]  

  • 9. Safety of intraperitoneal paclitaxel combined with conventional chemotherapy for colorectal cancer with peritoneal carcinomatosis: a phase I trial.
    Murono K; Nagata H; Ishimaru K; Emoto S; Kaneko M; Hiyoshi M; Sasaki K; Otani K; Shuno Y; Nishikawa T; Tanaka T; Hata K; Kawai K; Nozawa H; Muro K; Ishihara S
    Cancer Chemother Pharmacol; 2019 Jan; 83(1):145-150. PubMed ID: 30386886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4).
    Boku N; Ryu MH; Kato K; Chung HC; Minashi K; Lee KW; Cho H; Kang WK; Komatsu Y; Tsuda M; Yamaguchi K; Hara H; Fumita S; Azuma M; Chen LT; Kang YK
    Ann Oncol; 2019 Feb; 30(2):250-258. PubMed ID: 30566590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy and safety of CapeOX plus bevacizumab therapy followed by capecitabine plus bevacizumab maintenance therapy in patients with metastatic colorectal cancer: a multi-center, single-arm, phase II study (CCOG-0902).
    Nakayama G; Ishigure K; Yokoyama H; Uehara K; Kojima H; Ishiyama A; Hayashi N; Takano N; Hattori N; Kobayashi D; Tanaka C; Hayashi M; Kanda M; Yamada S; Sugimoto H; Koike M; Fujiwara M; Fujii T; Murotani K; Ando Y; Kodera Y
    BMC Cancer; 2017 Apr; 17(1):243. PubMed ID: 28376737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal function, body surface area, and age are associated with risk of early-onset fluoropyrimidine-associated toxicity in patients treated with capecitabine-based anticancer regimens in daily clinical care.
    Meulendijks D; van Hasselt JGC; Huitema ADR; van Tinteren H; Deenen MJ; Beijnen JH; Cats A; Schellens JHM
    Eur J Cancer; 2016 Feb; 54():120-130. PubMed ID: 26761784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Postoperative Adjuvant Chemotherapy for Stage III Colon Cancer--Drug Selection, Tolerability, and Safety in Clinical Practice].
    Okada K; Sadahiro S; Saito G; Tanaka A; Suzuki T
    Gan To Kagaku Ryoho; 2016 May; 43(5):587-92. PubMed ID: 27210088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial.
    Yamada Y; Denda T; Gamoh M; Iwanaga I; Yuki S; Shimodaira H; Nakamura M; Yamaguchi T; Ohori H; Kobayashi K; Tsuda M; Kobayashi Y; Miyamoto Y; Kotake M; Shimada K; Sato A; Morita S; Takahashi S; Komatsu Y; Ishioka C
    Ann Oncol; 2018 Mar; 29(3):624-631. PubMed ID: 29293874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
    Tsuruta A; Yamashita K; Tanioka H; Tsuji A; Inukai M; Yamakawa T; Yamatsuji T; Yoshimitsu M; Toyota K; Yamano T; Nagasaka T; Okajima M
    Drug Des Devel Ther; 2016; 10():3827-3835. PubMed ID: 27920498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of oral administration of cystine and theanine in colorectal cancer patients undergoing capecitabine-based adjuvant chemotherapy after surgery: a multi-institutional, randomized, double-blinded, placebo-controlled, phase II trial (JORTC-CAM03).
    Hamaguchi R; Tsuchiya T; Miyata G; Sato T; Takahashi K; Miura K; Oshio H; Ohori H; Ariyoshi K; Oyamada S; Iwase S
    Support Care Cancer; 2020 Aug; 28(8):3649-3657. PubMed ID: 31811480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Study of the Postoperative Adjuvant Chemotherapy with UFT/LV or Capecitabine for Stage III Colorectal Cancer].
    Maruyama T; Yasuda K; Sako A; Ueda K; Okumura M
    Gan To Kagaku Ryoho; 2016 Jan; 43(1):69-72. PubMed ID: 26809528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A Case of Colon Cancer with DPD Deficiency That Showed Severe Myelosuppression by CapeOX Adjuvant Chemotherapy after Colon Resection].
    Watanabe H; Arita S; Takeuchi T; Oshima Y; Koike N
    Gan To Kagaku Ryoho; 2018 Nov; 45(11):1661-1664. PubMed ID: 30449859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant CapeOx therapy followed by sphincter-preserving surgery for lower rectal cancer.
    Hata T; Takahashi H; Sakai D; Haraguchi N; Nishimura J; Kudo T; Chu M; Takemasa I; Taroh S; Mizushima T; Doki Y; Mori M
    Surg Today; 2017 Nov; 47(11):1372-1377. PubMed ID: 28474202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Practical use of capecitabine plus oxaliplatin (CAPEOX) with bevacizumab for patients with metastatic colorectal cancer that cannot expect conversion therapy.
    Yokomizo H; Yoshimatsu K; Otani T; Osawa G; Nakayama M; Matsumoto A; Yano Y; Okayama S; Naritaka Y
    Hepatogastroenterology; 2013; 60(128):1911-5. PubMed ID: 24719926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.